Anti-IL5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian Severe Asthma Registry.

BACKGROUND: Asthmatics have accelerated lung function decline over time compared with healthy individuals. OBJECTIVE: To evaluate risk factors for accelerated lung function decline. METHODS: In a longitudinal analysis on severe asthmatics enrolled in the Belgian Severe Asthma Registry with at least 2 visits a minimum of 12 months apart, we compared characteristics of patients with and without decline (loss of post-bronchodilation forced expiratory volume in 1 s [FEV1] (% predicted)/y greater than zero) over time. Multiple linear regression was applied to study the factors independently associa... Mehr ...

Verfasser: Graff, Sophie
Brusselle, Guy
Hanon, Shane
Sohy, Carine
Dupont, Lieven
Peche, Rudy
Michils, Alain
Pilette, Charles
Joos, Guy
Lahousse, Lies
Lapperre, Therese
Renaud, Louis
Schleich, Florence
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Verlag/Hrsg.: Elsevier Inc.
Schlagwörter: decline / eosinophils / lung function / mepolizumab / severe asthma
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26495719
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/251468